RADL3 Pharmacy Scale: 3,230 Stores in the FRE
Raia Drogasil (RADL3 / RD Saúde) discloses a national pharmacy platform in its 2025 FRE: 3,230 stores across all Brazilian states and the Federal District, 16.5% average national market share in 4Q24, and R$ 41.8 billion in gross revenue.
This page summarizes a real FRE business-model analysis. apicvm is the filings and extraction API; analysis is yours.
The research question
> Describe history, business model, strategy, competitive advantages, and market context from the FRE.
History markers
- Origins: Raia (1905) and Drogasil (1935); merger in 2011
- Specialty: 4Bio path started 2015, full acquisition completed 2024
- Onofre acquisition in 2019
- Corporate brand evolution to RD / RD Saúde
- Stated ambition: contribute most to a healthier Brazilian society by 2030, with a sustainability agenda of 22 commitments to 2030
Operating model
| Dimension | FRE disclosure |
|---|---|
| Core | Retail medicines, beauty, hygiene, dermocosmetics |
| Brands | Raia and Drogasil |
| Channels | Stores (primary), apps, websites, phone sales |
| Manufacturing | No own production; private label via ~100 suppliers |
| Logistics | 14 DCs, >240,000 m² |
| Footprint | 3,230 stores; Brazil-only |
Largest private-label supplier is about 6% of purchases — diversified sourcing. No customer >10% of net revenue.
Strategy fronts
- Omnichannel expansion (physical + digital + marketplace; "Nova Farmácia" / health platform)
- Specialty drugs via 4Bio; in-store health services (e.g. vaccination; ANVISA also authorized screening exams in pharmacies)
- RD Ventures for digital ecosystem investments (Cuco, Impulso, Dose Certa, among others cited)
- Sustainability commitments through 2030
Market backdrop
Brazilian pharma retail factory-price turnover cited at about R$ 208 billion in 2024 (~12% vs 2023). Competition includes other chains, independents, and adjacent channels (supermarkets, beauty, direct sales). Sanitary regulation (ANVISA and local rules) shapes what services pharmacies can offer.
Why FRE business text matters for RADL3
DFP footnotes show GLP-1 mix and earnings quality (covered elsewhere). The FRE business section adds:
- Store count and national share
- Logistics footprint
- Specialty and services strategy
- Explicit Brazil-only scope
Replicate with apicvm
export APICVM_KEY='apicvm_...'
export APICVM_URL='https://apicvm.dev'
curl -H "Authorization: Bearer $APICVM_KEY" \
"$APICVM_URL/v1/companies/resolve?query=RADL3&by=ticker"
curl -H "Authorization: Bearer $APICVM_KEY" \
"$APICVM_URL/v1/documents?ticker=RADL3&type=FRE&year=2025&perPage=50"List FRE sections, pick the business/history documents by name, extract pages. Prefer prefix routing over embedding the whole FRE.
Methodology note
Findings from a completed Hold analysis of RD Saúde's public 2025 FRE. Not investment advice.
Limitations
- Market share and store counts are point-in-time disclosures.
- No detailed forward financial projections in the analyzed business-section extract.
- Specialty and digital KPIs may update in later FRE versions or earnings releases.
Next steps
Ready to integrate?
Get an API key and start querying Brazilian CVM filings programmatically.